A platform designed to support APC-dependent discovery with greater consistency
CrossRelay is a scalable human cDC1-like APC platform designed to support antigen presentation, cross-presentation-relevant studies, and CD8-directed immune work through a more consistent human APC foundation.
The platform is intended to connect renewable APC biology, biologically relevant antigen handling, and operational scalability so that target evaluation, immune assay development, and translational studies can be pursued with a stronger APC layer.
A renewable human cDC1-like APC foundation underlies the platform
A renewable APC starting point
The platform foundation provides a cell system with features relevant to antigen uptake, antigen presentation, cross-presentation-relevant study design, and CD8-directed immune priming.
Its cDC1-like orientation is informed by biology associated with IRF8, BATF3, XCR1, CADM1, and ID2, providing a scientific framework relevant to antigen presentation and CD8-directed immune studies.
A renewable APC foundation can reduce dependence on donor-limited preparations when repeatability, scale, and APC consistency are important to the study.
The platform is intended to provide a more stable APC layer for workflows in which antigen handling and presentation logic shape the downstream result.
CrossRelay is positioned as a useful, scalable human APC platform for discovery and translational research, not as a literal replacement for primary human cDC1 in every context.
From APC foundation to downstream CD8-directed study utility
Renewable APC foundation
A scalable human APC starting point reduces the operational fragility of repeated primary-cell workflows.
Antigen handling
Uptake, processing context, antigen expression, and intracellular handling shape whether APC-dependent studies remain informative.
Presentation logic
Biology aligned with antigen presentation and cross-presentation-relevant study design can improve how APC-dependent questions are interpreted.
CD8-directed output
A stronger APC layer may improve the clarity, magnitude, or interpretability of downstream CD8 T-cell readouts.
Designed for APC-dependent questions across discovery and translation
Antigen and payload assessment
The platform can support evaluation of whether peptide, encoded, or more complex antigen formats are being handled in ways that remain relevant to downstream CD8-directed immunity.
Immune assay refinement
A stronger APC foundation can reduce uncertainty introduced by weak or inconsistent APC inputs when formats, conditions, or assumptions are compared.
CD8-directed workflow support
The platform can support experiments in which APC quality is expected to influence priming, expansion, activation, or downstream immune interpretation.
Broader translational studies
CrossRelay may support more informative translational studies where APC performance is expected to materially shape the outcome.
Observations relevant to platform performance
Human cDC1-like cell lines designed for repeatable APC-centered studies.
A predominant antigen-specific CD8 T-cell population is generated in two weeks.
Over 90% antigen expression can be achieved in cDC1-like APC.